34,044 Shares in SWK Holdings Co. (NASDAQ:SWKH) Bought by Victory Capital Management Inc.

Victory Capital Management Inc. acquired a new stake in SWK Holdings Co. (NASDAQ:SWKH) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 34,044 shares of the company’s stock, valued at approximately $589,000. Victory Capital Management Inc. owned about 0.27% of SWK as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. SkyView Investment Advisors LLC boosted its stake in SWK by 7.7% during the second quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock worth $529,000 after acquiring an additional 2,234 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in SWK by 85.7% during the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock worth $511,000 after purchasing an additional 13,892 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of SWK in the second quarter valued at approximately $172,000. Finally, Vanguard Group Inc. grew its stake in SWK by 75.5% in the 1st quarter. Vanguard Group Inc. now owns 397,273 shares of the company’s stock valued at $6,920,000 after purchasing an additional 170,957 shares during the period. Institutional investors own 99.27% of the company’s stock.

SWK Stock Performance

NASDAQ SWKH opened at $15.85 on Friday. The company has a 50-day simple moving average of $16.60 and a 200 day simple moving average of $16.93. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.06 and a current ratio of 5.06. SWK Holdings Co. has a 52-week low of $15.14 and a 52-week high of $18.75. The company has a market capitalization of $193.89 million, a PE ratio of 17.04 and a beta of 0.36.

SWK Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.